Rapid Improvement in Lipid Maculopathy Following Faricimab Therapy in Recalcitrant Familial Exudative Vitreoretinopathy

Ophthalmic Surg Lasers Imaging Retina. 2023 Jul;54(7):426-428. doi: 10.3928/23258160-20230609-01. Epub 2023 Jun 1.

Abstract

A monocular 22-year-old man with recalcitrant familial exudative vitreoretinopathy presented with progressive subretinal lipid exudation and lipid maculopathy that responded poorly to repeated aflibercept injections. The subretinal exudation started temporally and gradually progressed, involving the macula and the retinal periphery in all 4 quadrants. At the 22-month follow-up visit, macular and peripheral subretinal exudation persisted despite a total of 29 injections. Faricimab was then injected once every 2 weeks for a total of 3 injections, which resulted in rapid dramatic resolution of the macular and most of the peripheral subretinal exudation. No ocular or systemic adverse events were noted. [Ophthalmic Surg Lasers Imaging Retina 2023;54:426-428.].

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Familial Exudative Vitreoretinopathies
  • Humans
  • Lipids
  • Macular Degeneration*
  • Male
  • Retina
  • Retinal Diseases*
  • Young Adult

Substances

  • faricimab
  • Lipids